+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Involuntary weight loss between surgery and chemotherapy impairs overall survival of high-grade serous ovarian cancer patients



Involuntary weight loss between surgery and chemotherapy impairs overall survival of high-grade serous ovarian cancer patients



Gynecologic Oncology 141: 97-98




(PDF emailed within 0-6 h: $19.90)

Accession: 064870087

Download citation: RISBibTeXText

DOI: 10.1016/j.ygyno.2016.04.269


Related references

MON-P072: Involuntary Weight Loss Between Surgery and a day of 1st Cycle of Chemotherapy is an Independent Adverse Prognostic Factor for overall Survival in Ovarian Cancer. Clinical Nutrition 35: S179-S180, 2016

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium. Oncotarget 7(22): 32785-32795, 2017

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecologic Oncology 149(1): 155-162, 2018

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology 27(4): 625-634, 2016

Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology 141(3): 466-470, 2017

Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer. Applied Immunohistochemistry and Molecular Morphology 25(2): 110-116, 2015

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research 24(3): 569-580, 2017

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clinical Cancer Research 24(6): 1389-1401, 2017

Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiology, Biomarkers and Prevention 2019, 2019

Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival. Medicine 97(4): E9685, 2018

Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer. Gynecologic Oncology 126(1): 103-108, 2012

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. Journal of Gynecologic Oncology 27(1): E7, 2016

Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences 5(7): 904-908, 2018

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. Journal of Cancer Research and Clinical Oncology 2019, 2019